- Home
- LU vs CGON Comparison
LU vs CGON Comparison
Compare LU & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LU
- CGON
- Stock Information
- Founded
- LU 2005
- CGON 2010
- Country
- LU China
- CGON United States
- Employees
- LU N/A
- CGON N/A
- Industry
- LU Finance: Consumer Services
- CGON
- Sector
- LU Finance
- CGON
- Exchange
- LU Nasdaq
- CGON NYSE
- Market Cap
- LU 2.4B
- CGON 2.3B
- IPO Year
- LU 2020
- CGON 2024
- Fundamental
- Price
- LU $3.10
- CGON $27.85
- Analyst Decision
- LU Hold
- CGON Strong Buy
- Analyst Count
- LU 2
- CGON 10
- Target Price
- LU $2.98
- CGON $65.11
- AVG Volume (30 Days)
- LU 4.0M
- CGON 421.1K
- Earning Date
- LU 03-20-2025
- CGON 03-04-2025
- Dividend Yield
- LU 76.33%
- CGON N/A
- EPS Growth
- LU N/A
- CGON N/A
- EPS
- LU N/A
- CGON N/A
- Revenue
- LU $4,671,260,668.00
- CGON $684,000.00
- Revenue This Year
- LU N/A
- CGON $210.00
- Revenue Next Year
- LU $1.48
- CGON N/A
- P/E Ratio
- LU N/A
- CGON N/A
- Revenue Growth
- LU N/A
- CGON 258.12
- 52 Week Low
- LU $2.00
- CGON $25.77
- 52 Week High
- LU $4.94
- CGON $48.05
- Technical
- Relative Strength Index (RSI)
- LU 68.59
- CGON 41.49
- Support Level
- LU $2.78
- CGON $27.10
- Resistance Level
- LU $2.96
- CGON $29.42
- Average True Range (ATR)
- LU 0.13
- CGON 1.15
- MACD
- LU 0.06
- CGON -0.10
- Stochastic Oscillator
- LU 88.83
- CGON 29.02
About LU Lufax Holding Ltd each representing two (2)
Lufax Holding Ltd is a technology-empowered personal financial services platform in China. The company address the large unmet demand for personal lending among small business owners as well as salaried workers in China and provides tailor-made wealth management solutions to China's middle class and affluent population. Its platform has two hubs namely Retail Credit Facilitation Hub and Wealth Management Hub.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.